Resultados: 16

    COVID-19 treatment guidelines panel: Coronavirus diseases 2019 (COVID-19) treatment guidelines

    The COVID-19 Treatment Guidelines were developed to provide clinicians with guidance on caring for patients with COVID-19. Because clinical information about the optimal management of COVID-19 is evolving quickly, these Guidelines are updated frequently to reflect newly published data and other authorita...

    Maribavir for treating refractory cytomegalovirus infection after transplant

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant. Commercial arrangement There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...

    Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API) [Pré-print]

    Since the beginning of the COVID-19 pandemic, therapeutic options for treating COVID-19 have been investigated at different stages of clinical manifestations. Considering the particular impact of COVID-19 in the Americas, this document aims to present recommendations for the pharmacological treatment of ...

    Therapeutics and COVID-19: living guideline - 16 September 2022

    The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...

    COVID-19 rapid guideline: managing COVID-19. Last updated: 14 July 2022

    This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use ...

    American Society of Transplantation and Cellular Therapy series 4: Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation

    The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new...

    American Society for Transplantation and Cellular Therapy series: 3: Prevention of Cytomegalovirus infection and disease after Hematopoietic Cell Transplantation

    Transplant cell ther; 27 (9), 2021
    The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A n...

    Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

    Eur. respir. j; 57 (4), 2021
    Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of SARS-CoV-2 infection have a high mortality rate and frequently require noninvasive respiratory support or invasive ventilation. Optimising and standardising management through evidence-based guidelines may improve quality of ca...

    Clinical practice guideline on treating influenza in adult patients with Chinese patent medicines

    Pharmacol. res; 160 (), 2020
    Influenza is a major public health problem worldwide. Mutations and resistance development make the use of antiviral therapy challenging. Chinese patent medicines are often used to treat influenza in China and well tolerable. However, the misuse of Chinese patent medicines is common. We therefore aimed t...

    Remdesivir for severe COVID-19: a clinical practice guideline

    BMJ; 370 (), 2020
    Clinical question: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. Aft...